B M Best1, S Burchett2, H Li3, A Stek4, C Hu5, J Wang6, E Hawkins7, M Byroads8, D H Watts9, E Smith10, C V Fletcher11, E V Capparelli1, M Mirochnick12. 1. School of Medicine-Rady Children's Hospital and Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego, San Diego, CA, USA. 2. Harvard Medical School, Children's Hospital Boston, Boston, MA, USA. 3. Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA. 4. Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA. 5. Division of Epidemiology and Biostatistics, University of Arizona Mel & Enid Zuckerman College of Public Health, Tucson, AZ, USA. 6. Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, USA. 7. Social and Scientific Systems, Silver Springs, MD, USA. 8. Frontier Science & Technology Research Foundation, Amherst, NY, USA. 9. Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), Bethesda, MD, USA. 10. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. 11. College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. 12. Boston University School of Medicine, Boston, MA, USA.
Abstract
OBJECTIVES: Tenofovir disoproxil fumarate (TDF) is increasingly used in the highly active antiretroviral therapy (HAART) regimens of pregnant women, but limited data exist on the pregnancy pharmacokinetics of chronically dosed TDF. This study described tenofovir pharmacokinetics during pregnancy and postpartum. METHODS: International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s is a prospective, nonblinded pharmacokinetic study of HIV-infected pregnant women that included a cohort receiving 300 mg TDF once daily. Steady-state 24-hour pharmacokinetic profiles were measured at the second and third trimesters, postpartum, and in maternal and umbilical cord samples collected at delivery. Tenofovir was measured by liquid chromatography-mass spectrometry (LC-MS). The target area under the concentration versus time curve from time 0 to 24 h post dose (AUC) was ≥ 1.99 μg h/mL (nonpregnant historical control 10th percentile). RESULTS: The median tenofovir AUC was decreased during the second (1.9 μg h/mL) and third (2.4 μg h/mL; P = 0.005) trimesters versus postpartum (3.0 μg h/mL). Tenofovir AUC exceeded the target for two of four women (50%) in the second trimester, 27 of 37 women [73%; 95% confidence interval (CI) 56%, 86%] in the third trimester, and 27 of 32 women (84%; 95% CI 67%, 95%) postpartum (P > 0.05). Median second/third-trimester troughs were lower (39/54 ng/mL) than postpartum (61 ng/mL). Median third-trimester weight was greater for subjects below the target AUC versus those above the target (97.9 versus 74.2 kg, respectively; P = 0.006). The median ratio of cord blood to maternal concentrations was 0.88. No infants were HIV infected. CONCLUSIONS: This study found lower tenofovir AUC and troughs during pregnancy. Transplacental passage with chronic TDF use during pregnancy was high. Standard TDF doses appear to be appropriate for most HIV-infected pregnant women but therapeutic drug monitoring with dose adjustment should be considered in pregnant women with high weight (> 90 kg) or inadequate HIV RNA response.
OBJECTIVES:Tenofovir disoproxil fumarate (TDF) is increasingly used in the highly active antiretroviral therapy (HAART) regimens of pregnant women, but limited data exist on the pregnancy pharmacokinetics of chronically dosed TDF. This study described tenofovir pharmacokinetics during pregnancy and postpartum. METHODS: International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s is a prospective, nonblinded pharmacokinetic study of HIV-infected pregnant women that included a cohort receiving 300 mg TDF once daily. Steady-state 24-hour pharmacokinetic profiles were measured at the second and third trimesters, postpartum, and in maternal and umbilical cord samples collected at delivery. Tenofovir was measured by liquid chromatography-mass spectrometry (LC-MS). The target area under the concentration versus time curve from time 0 to 24 h post dose (AUC) was ≥ 1.99 μg h/mL (nonpregnant historical control 10th percentile). RESULTS: The median tenofovir AUC was decreased during the second (1.9 μg h/mL) and third (2.4 μg h/mL; P = 0.005) trimesters versus postpartum (3.0 μg h/mL). Tenofovir AUC exceeded the target for two of four women (50%) in the second trimester, 27 of 37 women [73%; 95% confidence interval (CI) 56%, 86%] in the third trimester, and 27 of 32 women (84%; 95% CI 67%, 95%) postpartum (P > 0.05). Median second/third-trimester troughs were lower (39/54 ng/mL) than postpartum (61 ng/mL). Median third-trimester weight was greater for subjects below the target AUC versus those above the target (97.9 versus 74.2 kg, respectively; P = 0.006). The median ratio of cord blood to maternal concentrations was 0.88. No infants were HIV infected. CONCLUSIONS: This study found lower tenofovir AUC and troughs during pregnancy. Transplacental passage with chronic TDF use during pregnancy was high. Standard TDF doses appear to be appropriate for most HIV-infected pregnant women but therapeutic drug monitoring with dose adjustment should be considered in pregnant women with high weight (> 90 kg) or inadequate HIV RNA response.
Authors: Angela P H Colbers; David A Hawkins; Andrea Gingelmaier; Kabamba Kabeya; Jürgen K Rockstroh; Christopher Wyen; Katharina Weizsäcker; S Tariq Sadiq; Jelena Ivanovic; Carlo Giaquinto; Graham P Taylor; José Moltó; David M Burger Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: Y Wang; E Livingston; S Patil; R E McKinney; A D Bardeguez; J Gandia; M J O'Sullivan; P Clax; S Huang; J D Unadkat Journal: J Infect Dis Date: 1999-11 Impact factor: 5.226
Authors: D Hirt; S Urien; D K Ekouévi; E Rey; E Arrivé; S Blanche; C Amani-Bosse; E Nerrienet; G Gray; M Kone; S K Leang; J McIntyre; F Dabis; J-M Tréluyer Journal: Clin Pharmacol Ther Date: 2008-11-05 Impact factor: 6.875
Authors: Tom Delahunty; Lane Bushman; Brian Robbins; Courtney V Fletcher Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-05-21 Impact factor: 3.205
Authors: J Moodley; D Moodley; K Pillay; H Coovadia; J Saba; R van Leeuwen; C Goodwin; P R Harrigan; K H Moore; C Stone; R Plumb; M A Johnson Journal: J Infect Dis Date: 1998-11 Impact factor: 5.226
Authors: Brookie M Best; Mark Mirochnick; Edmund V Capparelli; Alice Stek; Sandra K Burchett; Diane T Holland; Jennifer S Read; Elizabeth Smith; Chengcheng Hu; Stephen A Spector; James D Connor Journal: AIDS Date: 2006-02-28 Impact factor: 4.177
Authors: André Dallmann; Ibrahim Ince; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel Journal: Clin Pharmacokinet Date: 2017-11 Impact factor: 6.447
Authors: Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick Journal: AIDS Date: 2018-03-27 Impact factor: 4.177
Authors: Maria Pyra; Peter L Anderson; Craig W Hendrix; Renee Heffron; Kenneth Mugwanya; Jessica E Haberer; Katherine K Thomas; Connie Celum; Deborah Donnell; Mark A Marzinke; Elizabeth A Bukusi; Nelly R Mugo; Stephen Asiimwe; Elly Katabira; Jared M Baeten Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Lauren R Cirrincione; Anthony T Podany; Joshua P Havens; Sara H Bares; Shetty Ravi Dyavar; Yeongjin Gwon; Tanner M Johnson; N Jean Amoura; Courtney V Fletcher; Kimberly K Scarsi Journal: J Antimicrob Chemother Date: 2020-05-01 Impact factor: 5.790